274 related articles for article (PubMed ID: 33706221)
21. Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease.
Chan IP; Wu SY; Chang CC; Chen WY
Vet Rec; 2019 Sep; 185(11):343. PubMed ID: 31439824
[TBL] [Abstract][Full Text] [Related]
22. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease.
Mikawa S; Nagakawa M; Ogi H; Akabane R; Koyama Y; Sakatani A; Ogawa M; Miyakawa H; Shigemoto J; Tokuriki T; Toda N; Miyagawa Y; Takemura N
J Vet Cardiol; 2020 Aug; 30():92-99. PubMed ID: 32707334
[TBL] [Abstract][Full Text] [Related]
23. Selected hematological, biochemical, and echocardiographic variables as predictors of survival in canine patients with myxomatous mitral valve disease and congestive heart failure.
Brložnik M; Pečjak A; Nemec Svete A; Domanjko Petrič A
J Vet Cardiol; 2023 Apr; 46():18-29. PubMed ID: 37023673
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
[TBL] [Abstract][Full Text] [Related]
25. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
[TBL] [Abstract][Full Text] [Related]
26. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
[TBL] [Abstract][Full Text] [Related]
27. Validation of a focused echocardiographic training program in first opinion practice.
Dickson D; Harris J; Chang CH; Patteson M; Hezzell MJ
J Vet Intern Med; 2022 Nov; 36(6):1913-1920. PubMed ID: 36221315
[TBL] [Abstract][Full Text] [Related]
28. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
[TBL] [Abstract][Full Text] [Related]
29. Clinical presentation, echocardiographic findings, treatment strategies, and prognosis of dogs with myxomatous mitral valve disease presented with pericardial effusion due to suspected left atrial tear: a retrospective case-control study.
Czech AA; Glaus TM; Testa F; Romito G; Baron Toaldo M
J Vet Cardiol; 2024 Feb; 51():105-115. PubMed ID: 38128416
[TBL] [Abstract][Full Text] [Related]
30. Mitral annular disjunction and myxomatous mitral valve disease in a dog.
Pereira N
J Vet Cardiol; 2024 Feb; 51():9-12. PubMed ID: 37989026
[TBL] [Abstract][Full Text] [Related]
31. Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease.
Baron Toaldo M; Mazzoldi C; Romito G; Poser H; Contiero B; Cipone M; Guglielmini C
J Vet Intern Med; 2020 Sep; 34(5):1787-1793. PubMed ID: 32767718
[TBL] [Abstract][Full Text] [Related]
32. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
33. Change of Vertebral Left Atrial Size in Dogs With Preclinical Myxomatous Mitral Valve Disease Prior to the Onset of Congestive Heart Failure.
Lee D; Yun T; Koo Y; Chae Y; Ku D; Chang D; Kang BT; Yang MP; Kim H
J Vet Cardiol; 2022 Aug; 42():23-33. PubMed ID: 35675727
[TBL] [Abstract][Full Text] [Related]
34. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease.
Sargent J; Muzzi R; Mukherjee R; Somarathne S; Schranz K; Stephenson H; Connolly D; Brodbelt D; Fuentes VL
J Vet Cardiol; 2015 Mar; 17(1):1-12. PubMed ID: 25586168
[TBL] [Abstract][Full Text] [Related]
35. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
[TBL] [Abstract][Full Text] [Related]
36. QT instability, an indicator of augmented arrhythmogenesis, increases with the progression of myxomatous mitral valve disease in dogs.
Brüler BC; Jojima FS; Dittrich G; Giannico AT; Sousa MG
J Vet Cardiol; 2018 Aug; 20(4):254-266. PubMed ID: 30031743
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
[TBL] [Abstract][Full Text] [Related]
38. Prospective pilot study on the predictive significance of plasma miR-30b-5p through the study of echocardiographic modifications in Cavalier King Charles Spaniels affected by different stages of myxomatous mitral valve disease: The PRIME study.
Ghilardi S; Lecchi C; Bagardi M; Romito G; Colombo FM; Polli M; Franco C; Brambilla PG
PLoS One; 2022; 17(12):e0274724. PubMed ID: 36574372
[TBL] [Abstract][Full Text] [Related]
39. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension.
Poser H; Berlanda M; Monacolli M; Contiero B; Coltro A; Guglielmini C
J Vet Cardiol; 2017 Jun; 19(3):228-239. PubMed ID: 28579307
[TBL] [Abstract][Full Text] [Related]
40. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
J Am Heart Assoc; 2021 May; 10(9):e018923. PubMed ID: 33890477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
